Table 4.
Efficacy estimates in main analysis (n=1083) of meta-analysis using individual patient data on efficacy of naftidrofuryl compared with placebo for treatment of intermittent claudication
| Relative improvement analysis | One stage approach | Two stage approach |
|---|---|---|
| Ratio of relative improvement in pain-free walking distance (95% CI)* | 1.37 (1.27 to 1.49) | 1.38 (1.24 to 1.56) |
| Ratio of relative improvement in maximal walking distance (95% CI)† | 1.40 (1.19 to 1.63) | 1.38 (1.18 to 1.61) |
| Responder analysis: | ||
| Absolute difference in response rates (95% CI) | 22.3 (17.1 to 27.6) | 24.8 (12.2 to 37.4) |
| Number needed to treat (95% CI) | 4.48 (3.62 to 5.85) | 4.03 (2.51 to 8.19) |
| Relative benefit (95% CI) | 1.75 (1.50 to 2.03) | 1.84 (1.36 to 2.45) |
| Odds ratio (95% CI) | 2.65 (2.10 to 3.37) | 2.90 (1.70 to 4.94) |
*Ratio of final pain-free walking distance over baseline pain-free walking distance after use of naftidrofuryl compared with placebo.
†Ratio of final maximal walking distance over baseline maximal walking distance after use of naftidrofuryl compared with placebo.